EGFR and non-small cell lung carcinoma: In addition, the employment of combined ICIs and chemotherapy did not change the prognosis as well: in the IMpower130 trial, atezolizumab combined with chemotherapy did not improve the 32 patients’ survival with EGFR mutated or ALK-rearranged NSCLC [26].